Pre-market: Stemcells completes trial enrollment
Shares of Stemcells Inc. (Nasdaq: STEM) have appreciated on news this morning that the pharmaceutical company has successfully completed enrollment for a Phase I clinical trial of its treatment for Batten disease, a fatal disorder of the nervous systems. Shares are up $0.02, or 1%, to $2.46.
Shares of Canadian pharmaceutical company Labopharm Inc. (Nasdaq: DDSS) are higher following news over the weekend that it has received a notice of compliance from regulators for its pain management tablets and can now begin marketing. Shares are up $0.16, or 6%, to $2.89.
Shares of CV Therapeutics, Inc. (Nasdaq: CVTX) have gained ground following news this morning that the Palo Alto, Calif.-based company has received a favorable mention from TV pundit Jim Cramer. The stock is up $0.61, or 6%, to %11.37.
ChipMOS TECHNOLOGIES LTD. (Nasdaq: IMOS), which provides semiconductor testing and assembly services, reported after Friday’s closing bell that its revenue for the month of May rose to $59.8 million, 27.2% higher than the $47 million in the same month of 2006. Shares are up $0.13, or 2%, to $6.51.
The Woodlands, Texas-based Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced on Sunday, June 17, that it has reached a financing agreement with investment firm The Invus Group LLC that will allow it to invest $205 million in 2007 and up to $345 million over the next years. Shares are up $0.09, or 3%, to $3.08.
Shares of San Diego-based Vical Inc. (Nasdaq: VICL) are trading in negative territory despite news over the weekend that the pharmaceutical company’s Phase 3 drug trial met its primary endpoint. The stock is down $0.01, or 0.20%, to $4.99.
